Market Newsdesk

NEWTON, Mass., Feb. 02, 2021 (GLOBE NEWSWIRE) — Allena Pharmaceuticals, Inc. (NASDAQ: ALNA), a late-stage, biopharmaceutical company dedicated to developing and commercializing first-in-class, oral enzyme therapeutics to treat patients with rare and severe metabolic and kidney disorders, today announced the appointment of Richard D. Katz, M.D., as Chief Financial Officer (CFO), effective immediately. Dr. Katz succeeds Edward Wholihan, whose planned departure was announced by the Company in November 2020.

“Rich is a terrific addition to Allena. He is a strategic leader with deep experience guiding corporate and business strategy for public biotechnology companies, and a proven track record of building well-funded, sustainable organizations,” said Louis Brenner, M.D., President and Chief Executive Officer of Allena Pharmaceuticals. “Rich’s integrated perspective as a physician and seasoned financial professional will bring great value as we continue to invest in our growing pipeline of oral enzyme therapeutics, with the goal of advancing reloxaliase from pivotal Phase 3 trials to commercialization, while also devoting increased resources to ALLN-346 and our next wave of therapeutic candidates.”

Dr. Katz brings more than 20 years of experience in healthcare finance and corporate development to Allena. Most recently, he served as CFO at Liquidia Technologies, Inc., a late-stage clinical biopharmaceutical company. Prior to Liquidia, Dr. Katz served as CFO at several biopharmaceutical companies, including Argos Therapeutics, Viamet Pharmaceuticals and Icagen, Inc. At Icagen, Dr. Katz played a key role in facilitating the company’s initial public offering and subsequent financings, the formation of several strategic collaborations and the company’s sale to Pfizer. Dr. Katz began his career as a vice president in the healthcare investment banking group at Goldman, Sachs & Company, where he executed a broad range of transactions, including equity and debt financings, mergers and acquisitions and corporate restructurings. He holds his B.A. from Harvard University, his M.D. from Stanford University School of Medicine and his M.B.A. from Harvard Business School.

“I am thrilled to join Allena, especially at this exciting time for the company,” said Richard Katz, M.D. “Based on the scientific and clinical data presented to-date, I believe that reloxaliase has the potential to provide a first-in-class medicine for people with enteric hyperoxaluria, a substantial population for whom current treatment options are extremely limited, and that ALLN-346 may address the unmet needs of patients living with both hyperuricemia and chronic kidney disease. I am excited to work with the team to advance these programs through clinical studies and toward successful launches. Moreover, I believe the company’s proprietary enzyme technology could fuel a broader pipeline of novel, orally delivered medicines and I look forward to working with my new colleagues to harness its full potential to address a range of rare and severe metabolic and kidney disorders.”

In connection with Dr. Katz joining Allena, Allena’s Board of Directors approved, effective as of February 1, 2021, the grant of a non-qualified stock option awarded to purchase 400,000 shares of its common stock to Dr. Katz under the Allena Pharmaceuticals 2021 Inducement Equity Plan. The stock option will be granted as an inducement material to Dr. Katz becoming an employee of Allena in accordance with Nasdaq Listing Rule 5635(c)(4). The option will have an exercise price equal to $1.67, which was the closing price of Allena’s common stock on The Nasdaq Global Select Market on February 1, 2021. The option will vest over a 4-year period, with 25% of the shares vesting after 12 months and the remaining shares vesting monthly over the following 36-months, subject to Dr. Katz’s continued employment with Allena on such vesting dates. The option is subject to the terms and conditions of the Inducement Plan and the terms and conditions of a stock option agreement covering the grant.

About Allena Pharmaceuticals

Allena Pharmaceuticals, Inc. is a late-stage biopharmaceutical company dedicated to developing and commercializing first-in-class, oral enzyme therapeutics to treat patients with rare and severe metabolic and kidney disorders. Allena’s lead product candidate, reloxaliase, is currently being evaluated in a pivotal Phase 3 clinical program for the treatment of enteric hyperoxaluria, a metabolic disorder characterized by markedly elevated urinary oxalate levels and commonly associated with kidney stones, chronic kidney disease and other serious kidney disorders. Allena is also developing ALLN-346 for the treatment of hyperuricemia in the setting of gout and advanced chronic kidney disease, with Phase 1b multiple-ascending dose and Phase 2 proof-of-concept studies planned for 2021.

Forward Looking Statements:

This release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, including, without limitation, statements concerning the future clinical, regulatory and commercial potential of reloxaliase, statements regarding the Allena’s development of ALLN-346, statements regarding Allena’s financial position and need for capital. Any forward-looking statements in this press release are based on management’s current expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to: market and other conditions, the timing for completion of Allena’s clinical trials of its product candidates, risks associated with obtaining, maintaining and protecting intellectual property; risks associated with Allena’s ability to enforce its patents against infringers and defend its patent portfolio against challenges from third parties; the risk of competition from other companies developing products for similar uses; risk associated with Allena’s financial condition and its need to obtain additional funding to support its business activities, including the future clinical development of reloxaliase and its ability to continue as a going concern; risks associated with Allena’s dependence on third parties; and risks related to the COVID-19 coronavirus. For a discussion of other risks and uncertainties, and other important factors, any of which could cause Allena’s actual results to differ from those contained in the forward-looking statements, see the section entitled “Risk Factors” in Item 1A of Part I of Allena’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2020, as well as discussions of potential risks, uncertainties and other important factors in Allena’s subsequent filings with the Securities and Exchange Commission. All information in this press release is as of the date of the release, and Allena undertakes no duty to update this information unless required by law.

Investor Contact

Hannah Deresiewicz
Stern Investor Relations, Inc.
212-362-1200
[email protected]

Media Contact

Adam Daley
Berry & Company Public Relations
212-253-8881
[email protected]

FORT WAYNE, Ind., Feb. 02, 2021 (GLOBE NEWSWIRE) — Franklin Electric Co., Inc. (NASDAQ: FELE) will release its fourth quarter and fiscal year 2020 earnings at 8:00 am ET on Tuesday, February 16, 2021. A conference call to review earnings and other developments in the business will commence at 9:00 am ET. The fourth quarter and fiscal year 2020 earnings call will be available via a live webcast. The webcast will be available in a listen only mode by going to:

https://edge.media-server.com/mmc/p/dn9qs2nn

If you intend to ask questions during the call, please dial in using 877.643.7158 for domestic calls and 914.495.8565 for international calls. The conference ID is: 2573897.

A replay of the conference call will be available Tuesday, February 16, 2021 at 12:00 noon ET through noon ET on Tuesday, February 23, 2021, by dialing 855.859.2056 for domestic calls and 404.537.3406 for international calls. The replay passcode is: 2573897.

Franklin Electric is a global leader in the production and marketing of systems and components for the movement of water and fuel. Recognized as a technical leader in its products and services, Franklin Electric serves customers around the world in residential, commercial, agricultural, industrial, municipal, and fueling applications.

“Safe Harbor” Statement under the Private Securities Litigation Reform Act of 1995. Any forward-looking statements contained herein, including those relating to market conditions or the Company’s financial results, costs, expenses or expense reductions, profit margins, inventory levels, foreign currency translation rates, liquidity expectations, business goals and sales growth, involve risks and uncertainties, including but not limited to, risks and uncertainties with respect to general economic and currency conditions, various conditions specific to the Company’s business and industry, weather conditions, new housing starts, market demand, competitive factors, changes in distribution channels, supply constraints, effect of price increases,  raw material costs, technology factors, integration of acquisitions, litigation, government and regulatory actions, the Company’s accounting policies, future trends, epidemics and pandemics, and other risks which are detailed in the Company’s Securities and Exchange Commission filings, included in Item 1A of Part I of the Company’s Annual Report on Form 10-K for the fiscal year ending December 31, 2019, Exhibit 99.1 attached thereto and in Item 1A of Part II of the Company’s Quarterly Reports on Form 10-Q. These risks and uncertainties may cause actual results to differ materially from those indicated by the forward-looking statements. All forward-looking statements made herein are based on information currently available, and the Company assumes no obligation to update any forward-looking statements.

Contact	:	John J. Haines
		Franklin Electric Co., Inc.
		260.824.2900

BOSTON, Feb. 02, 2021 (GLOBE NEWSWIRE) — Nationally-recognized securities law firm Block & Leviton LLP (www.blockleviton.com) announces that a lawsuit for violation of the federal securities laws has been filed against Tricida, Inc. (NASDAQ: TCDA) and certain of its executives.

On July 15, 2020, Tricida, Inc. (NASDAQ: TCDA) stunned the market when it announced that it had received a notification from the U.S. Food and Drug Administration that, as part of the FDA’s review of Tricida’s New Drug Application for its drug candidate, veverimer, “the FDA has identified deficiencies that preclude discussion of labeling and postmarketing requirements/commitments at this time.” On this news, Tricida’s stock price fell $10.56 per share, or over 40%.

Then on October 29, 2020, Tricida announced an update on its End-of-Review Type A meeting with the FDA concerning the veverimer New Drug Application, stating that Tricida “now believes the FDA will also require evidence of veverimer’s effect on CKD progression from a near-term interim analysis of the” trial for approval under the FDA’s Accelerated Approval Program, and that the “FDA is unlikely to rely solely on serum bicarbonate data for determination of efficacy.” Tricida also disclosed that it was “significantly reducing its headcount from 152 to 59 people and will discuss its commitments with vendors and contract service providers to potentially provide additional financial flexibility.” On this news, Tricida’s stock price fell another $3.90 per share, or over 47%, to close at just $4.37.

A lawsuit has been filed against Tricida and certain of its executives in the U.S. District Court for the Northern District of California. The lawsuit is captioned Pardi v. Tricida, Inc., et al., No. 3:21-cv-00076 (N.D. Cal.). The suit alleges that Tricida misled investors as to the viability of its veverimer NDA and that the NDA was materially deficient when presented.

If you purchased or acquired shares of Tricida between September 4, 2019 and October 28, 2020 and lost money, you are strongly encouraged to contact the nationally-recognized securities law firm Block & Leviton LLP (www.blockleviton.com) at (617) 398-5600, via email at [email protected], or at https://www.blockleviton.com/cases/tcda. The deadline to move the Court to be appointed lead plaintiff is March 8, 2021.

Block & Leviton LLP is a firm dedicated to representing investors and maintaining the integrity of the country’s financial markets. The firm represents many of the nation’s largest institutional investors as well as individual investors in securities litigation throughout the United States. The firm’s lawyers have recovered billions of dollars for its clients.

This notice may constitute attorney advertising.

CONTACT:
BLOCK & LEVITON LLP
260 Franklin St., Suite 1860
Boston, MA 02110
Phone: (617) 398-5600
Email: [email protected]
SOURCE: Block & Leviton LLP
www.blockleviton.com 

Tampa, FL, Feb. 02, 2021 (GLOBE NEWSWIRE) — Accounts Payable can be considered the backbone of any company, which means improving the efficiency and productivity of this critical department can make a significant impact on your success. Eliminating manual data entry, reducing bottlenecks, and increasing your bottom line are just a few reasons why AP Automation should be a top priority in 2021.

There are many tools to help you manage your Accounts Payable department, including document management, approval routing, workflow automation, and more. But what is the right combination for your company? How do you start an AP Automation project? What are the common pitfalls when implementing AP Automation? And how do you justify the ROI to senior management?

Join us on February 23rd at 4 p.m. EST for AP Automation for Oracle EBS: A Proven Methodology for Success, where our automation experts will explore the pain points that you should consider to develop an actionable plan for automating in 2021.

You will learn about a proven methodology for AP Automation for Oracle EBS, including discovery, implementation, training, and more:

• Learn why many implementations fail and how to avoid making the same mistakes
• Understand how business goals need to drive technical implementations
• Discover why real-time integration with Oracle EBS is imperative when looking for immediate ROI
• Identify and review your steps for managing AP Automation to eliminate redundancy
• Create a clearly defined roadmap for implementing AP Automation tools
• Review the potential ROI for an AP Automation project

Join us for AP Automation for Oracle EBS: A Proven Methodology for Success and you will walk away with a complete understanding of a paperless AP automation process and how you can create a business case to take to your senior management team.

Register Here: https://www2.intellichief.com/SROATUG022021

Not an SROATUG Member? Click here.

About IntelliChief

IntelliChief is the emerging leader in Enterprise Content Management (ECM) and Workflow Automation solutions. Leveraging advanced OCR, powerful workflows, document management, and analytics, IntelliChief eliminates manual processes and automates repetitive, time-consuming tasks to help businesses secure a decisive competitive advantage.

As a trusted Oracle Gold Partner and Infor Solution Partner, IntelliChief is recognized for its robust, configurable solutions and secure integrations with all ERP systems and applications. Hundreds of customers in every industry depend on IntelliChief as a strategic partner to help them digitize documents, standardize business processes, and automate Accounts Payable, Sales Orders, Human Resources, and more.

The IntelliChief team is committed to serving our customers, community, and country by guiding them through digital transformation and exemplifying what is possible with an ardent dedication to innovation and progress.

Connect with IntelliChief:

IntelliChief Resource Library | Blog | LinkedIn | Twitter 

 

For more information, visit https://www.intellichief.com/.

Zachary Leete
IntelliChief
2394049545
[email protected]

Live multi-angle video customer support accelerates machine repairs, reduces downtime, improves remote training and facilitates long distance collaboration

DETROIT, Feb. 02, 2021 (GLOBE NEWSWIRE) — ADTANCE, a leading international After-Sales Service technology platform provider for manufactures, industrial companies and mechanical engineering organizations, today announced a new ADTANCE Support Module and Fieldstreaming solution that is fully integrated into the ADTANCE Smart Services Platform 4.0. The ADTANCE Fieldstreaming solution is the first live remote support software capable of connecting every type of camera to the system, including cameras within smartphones, tablets, computers, security cameras, drones and underwater Remote Operated Vehicles (ROVs).

ADTANCE Support users can live stream views of machines from various angles simultaneously– significantly improving live support, remote training and long distance collaboration in the field. The solution can be implemented by using mobile devices such as smartphones and tablets or by wearing smartglasses.

“We’ve seen customer demand for live remote support, training and collaboration skyrocket – in part because of the current COVID-19 challenges, but also due to increasingly complex machines and a shortage of highly skilled technicians,” said Nils Arnold, Co-founder and CEO of ADTANCE. “Our new ADTANCE Support and Fieldstreaming solution is uniquely suited to address the growing set of remote service use cases. Companies want service technicians to be able to view machines from a variety of angles in real-time, conduct live remote user training from multiple perspectives, and collaborate remotely using multiple cameras. Our new Support Module and Fieldstreaming Solution makes all these use cases possible and simple.”

“ADTANCE’s Fieldstreaming Solution is a game-changer for us,” said Michael Ntagas, Director of After Sales Service at Reifenhäuser Group. “Now we are able to build an entire machine – sixteen meters high – and get the technical assistance we need 100% remotely. After the machine is built, we can remotely educate and train machine operators; effectively collaborate long distance with our customers to test new mixtures of raw materials running in the machine; and upgrade machines without traveling to the customer site. ADTANCE Support and Fieldstreaming Solution reduces the significant costs and current risks of traveling to customer sites, while increasing the number of customers our highly technical experts can service.”

The ADTANCE Support Module also includes the following new capabilities that improve communication and collaboration between service technicians and customers.

Expanded Support Session Communications

Users can now start an ADTANCE Support session by sending a message, document, or video recording in addition to initiating a session through a video call. Users do not need to download an app, as ADTANCE Support now runs on all browsers and mobile devices. Invitations to sessions can be shared by simply sending a link without the need to set up a user account. At any time during a session, users can send messages, documents, recordings, open a live video chat or collaborate using a digital whiteboard.

Snapshots During Live Video Stream

Snapshots can be taken at any time during the ADTANCE Support live video stream and users can mark up the video with circles, arrows or pertinent notes. Several people can work on a snapshot within the support session at the same time. A service technician simply sends a request to the field worker and once it is accepted, the system automatically executes a snapshot. Alternatively, users have the option to immediately accept all snapshots for a session prior to starting the video call. This allows the service expert to take snapshots at any time during the live video stream.

Reactivate Closed Sessions Anytime

ADTANCE Support now allows closed sessions to be reactivated and viewed again at any time. The documentation remains in place and participants can be invited back into the session. This saves time and significantly improves customer service, especially when there is a complex or recurring problem with the same customer.

“The new capabilities in ADTANCE Support are very impressive,” said Stephan Czwick, Product Manager at Schuler Group. “The ability to rejoin closed sessions is particularly valuable. A technician can view or restart a session days later and still have all the important information of the case intact, which allows the service expert to immediately pick up where they left off with the customer. This can save our technicians a tremendous amount of time and improve customer satisfaction.”

Broad Language Translation

ADTANCE Support now includes translation for 147 different languages. Users simply select a language, speak, then click a button and the system translates their speech into the selected language. This unparalleled language support enables companies to leverage their highly technical experts on a global basis.

ADTANCE Smart Service Platform 4.0

The ADTANCE Smart Service Platform 4.0 is the only centralized platform for digitizing the entire After-Sales Service lifecycle and encompasses the following modules:

• ADTANCE Support – Enables live remote support, inspection and maintenance for customers, utilizing devices such as smartglasses and multi-camera fieldstreaming.
• ADTANCE Workflow – Digitizes, analyzes and optimizes all workflows, including everyday processes, such as maintenance instructions.  
• ADTANCE Process Visualization and Monitoring (PVM) – Monitors the performance of individual machines as well as entire industrial plants.
• ADTANCE Predictive Maintenance (PM) – Analyzes and evaluates operational data in real time through the continuous monitoring of machines or the entire production plant using built-in sensors. Machine learning-based analysis offer predictions about potential downtime as well as warnings if a piece of equipment will require maintenance. 
• ADTANCE Ticketing – Standardizes entire customer service channels by bundling different channels into one system, including e-mail, telephone, SMS and social media. Creates order and clarity by providing different escalation levels with the respective reaction and resolution times.
• ADTANCE Document Management (DM) – Stores all customer service documents centrally, as well as control the access rights for security and privacy purposes. 
• ADTANCE Parts – A central catalogue system to ensure that all spare part information remains centrally located and easily discoverable.

Companies can start with a single ADTANCE software module and build up to the full solution or integrate individual ADTANCE modules into an existing system. The ADTANCE platform also enables companies to exchange data between systems, including competing systems.

Availability

ADTANCE Smart Services Platform 4.0 with the integrated Support Module and Fieldstreaming solution is immediately available directly from ADTANCE.

About ADTANCE

ADTANCE is a leading international After-Sales Service technology platform provider for manufactures, industrial companies and mechanical engineering organizations. The ADTANCE Smart Service Platform is the only solution that digitizes the entire After Sales Service lifecycle from live remote support to predictive maintenance and resource planning. More than 500 companies in industries such as manufacturing, automotive, chemical, mechanical engineering, oil and gas rely on ADTANCE solutions. Founded in 2015, ADTANCE is privately held with headquarters in Wald-Michelbach, Germany and offices in Detroit, Michigan USA as well as Stade, Germany. For more information, visit www.adtance.com and follow @adtance.

Media Contact:

Michele Nachum
Reichert Communications, LLC
[email protected]

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/690fa287-2bf5-4050-8079-a9adc9edecdc

CAMBRIDGE, Mass. and BERLIN, Feb. 02, 2021 (GLOBE NEWSWIRE) — ZAGENO, a leading enterprise marketplace solution connecting eCommerce to life science, today announced Chris Wasley’s appointment as its Chief Financial Officer.

For ZAGENO, Chris brings a deep business finance background as a former investment banker with particular expertise in scaling companies, fundraising, and cash management from his time at Tesla.

Chris arrives to ZAGENO following senior leadership roles in the energy sector, including as CFO at Metrus Energy, where he built and deployed cash management strategies to secure and maintain growth and increase return-on-investment for the company. During his time at high-growth companies such as Tesla and SolarCity, he focused on capital markets and financial product strategy. As such, Chris brings extensive capital raising experience, which complements his investment banking background with San Francisco area firms, Raymond James, and Cowen and Company.

“As ZAGENO grows, so does its need for capital structure and business model expansion,” said Florian Wegener, Co-Founder and CEO of ZAGENO. “As such, Chris will be instrumental in helping ZAGENO accelerate its growth and value to shareholders.”

ZAGENO and its people are recipients of several recent industry accolades. These include recognition by EY as a finalist for Entrepreneur Of The Year^® 2020 New England, a distinct honor as a Top 25 Women Leader in Biotechnology of 2020 by The Healthcare Technology Report, and the 2020 Life Science recipient eCommerce Global Customer Value Leadership Award from Frost and Sullivan.

About ZAGENO

ZAGENO is on a mission to accelerate scientific innovation by streamlining biotech purchasing processes with its award-winning, first-of-its-kind eCommerce platform. With approximately 25 million product SKUs from 5,000 unique brands, ZAGENO makes online shopping convenient, efficient, and reliable for any research material. The ZAGENO experience includes its Scientific Score, a best-in-class product rating system that offers unbiased, peer-reviewed ratings to support accurate purchasing decisions. Available on desktop, tablet, and mobile devices, ZAGENO makes biotech purchases easier than ever and is an ideal sales channel for suppliers and partners. Founded in 2015, ZAGENO has offices in Cambridge, Massachusetts, Berlin, Germany, and Wroclaw, Poland. Visit ZAGENO on the web at zageno.com; follow ZAGENO on social media at LinkedIn, Twitter, Instagram, and Facebook.

For more information:
Greg Vitarelli
[email protected]
+1 617 455 9627

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/0e28defe-fd27-409d-a312-f7cf62d670ee

BETHESDA, Md., Feb. 02, 2021 (GLOBE NEWSWIRE) — Gain Therapeutics, Inc. (“Gain”) today announced the addition of Dov Goldstein, M.D., Gwen Melincoff, Claude Nicaise, M.D. and Hans Peter Hasler as independent members to its Board of Directors. The new board additions will provide strategic guidance as the company focuses on identifying and optimizing allosteric binding sites that have never before been targeted to unlock new treatment options for difficult-to-treat disorders characterized by protein misfolding. In conjunction with the new additions, Dr. Lorenzo Leoni and Dr. Marianne Bjordal will be stepping down from Board.

“We are pleased to welcome such a distinguished group of board members at this pivotal time for Gain,” said Eric Richman, Chief Executive Officer at Gain. “Their decades of experience across the biopharmaceutical industry will be invaluable as we continue to advance our pipeline and determine how our proprietary Site-Directed Enzyme Enhancement Therapy (See-Tx™) computational platform technology can best be leveraged to help patients in need of new treatment options. I look forward to working with Dr. Goldstein, Ms. Melincoff, Dr. Nicaise and Mr. Hasler.”

Dr. Khalid Islam, Chairman of the Board, added, “I would like to thank Dr. Lorenzo Leoni and Dr. Marianne Bjordal for their important contributions and guidance during the last several years. With the addition of Dr. Goldstein, Ms. Melincoff, Dr. Nicaise and Mr. Hasler to our board, Gain is ideally positioned to build upon the considerable growth we’ve achieved over the past year. I am confident that these new directors will provide valuable insights and perspectives given their track records in research, clinical, regulatory and commercial. I look forward to their engagement and assistance in guiding our strategies and objectives to advance our pipeline of innovative and breakthrough therapies as Gain therapeutics continues its ongoing evolution.”

Biographical Information

Dr. Goldstein brings more than two decades of experience in the biotech industry to the Gain board of directors. He is currently the Chief Financial and Business Officer of Indapta Therapeutics, a biotechnology company focused on developing and commercializing a proprietary, off-the-shelf, allogeneic FcRγ-deficient natural killer (G-NK) cell therapy to treat multiple cancers and serves on the board of NeuBase Therapeutics. Prior to Indapta, Dr. Goldstein served as Chief Executive Officer at RIGImmune. From 2006-2019, he worked at Aisling Capital, a private investment firm. Dr. Goldstein also served as the Chief Financial Officer of Loxo Oncology, Inc. and Vicuron Pharmaceuticals, Inc., which was acquired by Pfizer, Inc. in September 2005. Dr. Goldstein has served as a director at ADMA Biologics, Inc., Esperion Therapeutics, Inc., and Cempra, Inc. (which was acquired by Melinta Therapeutics, Inc.). Dr. Goldstein received a B.S. from Stanford University, an M.B.A. from Columbia Business School, and an M.D. from Yale School of Medicine. He completed an internship in the Department of Medicine at Columbia-Presbyterian Hospital.

Ms. Melincoff is a seasoned business development and venture professional with over 25 years of deal-making and management experience in the biotechnology and pharmaceutical industries. Ms. Melincoff is currently managing director at Gemini Advisors LLC, a biopharmaceutical consultancy, and an advisor to Verge Genomics, a startup drug discovery company and Agent Capital. Previously, Ms. Melincoff served as Vice President of Business Development at BTG International Inc., a UK-specialist healthcare company. Prior to BTG, Ms. Melincoff was Senior Vice President of Corporate Development at Shire Plc (acquired by Takeda). Additionally, she led the Shire Strategic Investment Group, the venture capital arm of Shire Plc. Ms. Melincoff was Vice President of Business Development at Adolor Corporation and held executive positions at Eastman Kodak for over ten years in a number of their health care companies. She serves on the board of directors of several biopharmaceutical companies, including Protalix Biotherapeutics, Inc., Collegium Pharmaceutical, Inc. and Soleno Therapeutics, Inc. and has previously served on the boards of Photocure ASA, Kamada Ltd. and Tobira Therapeutics Inc. Ms. Melincoff holds a B.S. in Biology from The George Washington University and an M.S. in Management and Health Care Administration from Pennsylvania State University.

Dr. Nicaise is the founder of Clinical Regulatory Services, a company providing advice on clinical and regulatory matters to biotechnology companies. Dr. Nicaise serves on the board for Sarepta Therapeutics, Inc., chairs their Compensation committee, and is a member of their Research and Development committee. Since 2015, Dr. Nicaise has served as an Executive Vice President Regulatory at Ovid Therapeutics Inc., a company that develops medicines for orphan diseases of the brain. Dr. Nicaise was a Senior Vice President of Strategic Development and Global Regulatory Affairs at Alexion Pharmaceuticals from 2008 to 2014. From 1983 to 2008, Dr. Nicaise served in various positions of increasing responsibility at Bristol-Myers Squibb, including senior positions such as Vice President of Global Development, Vice-President of Worldwide Regulatory Science and Strategy, and leadership positions in Oncology, Infectious Disease, and Neuroscience development. Dr. Nicaise received his medical degree from the Université Libre de Bruxelles in Belgium.

Mr. Hasler was the Chief Executive Officer of Vicarius Pharma AG, a privately held European Bio-Pharma company until 2020. He also is a Senior Advisor of SBTech Global Advisory. His prior experiences include Elan Corporation, Dublin, where he was Chief Operating Officer, and Biogen Inc., Boston, where his positions included Chief Operating Officer, and EVP, Head of Global Neurology and International. Previously, Mr. Hasler was at Wyeth Pharmaceuticals, Radnor/PA, as Senior Vice President, Chief Marketing Officer and Managing Director of Wyeth Group Germany, Münster. Mr. Hasler is Chairman of the Board of HBM Healthcare Investments AG in Switzerland (SIX), Chairman of the Board of Shield Therapeutics, London (AIM), and a Director of Minerva Neurosciences in Boston (Nasdaq). He holds a Federal Swiss Commercial Diploma and a Marketing Manager Certificate from the Swiss Institute of Business Economy SIB, Zurich.

About Gain Therapeutics, Inc.

Gain Therapeutics is redefining drug discovery with its See-Tx™ target identification platform. By identifying and optimizing allosteric binding sites that have never before been targeted, Gain is unlocking new treatment options for difficult-to-treat disorders characterized by protein misfolding. Gain was originally established in 2017 with the support of its founders and institutional investors such as TiVenture, 3G Future Health Fund (previously known as Helsinn Investment Fund) and VitaTech. It has been awarded funding support from The Michael J. Fox Foundation for Parkinson’s Research (MJFF) and The Silverstein Foundation for Parkinson’s with GBA, as well as from the Eurostars-2 joint program with co-funding from the European Union Horizon 2020 research and Innosuisse. In July 2020, Gain Therapeutics, Inc. completed a share exchange with Gain Therapeutics, SA, a Swiss corporation, whereby GT Gain Therapeutics SA became a wholly owned subsidiary of Gain Therapeutics, Inc. For more information, visit https://www.gaintherapeutics.com/.

Forward-Looking Statements

Any statements in this release that are not historical facts may be considered to be “forward-looking statements.” Forward-looking statements are based on management’s current expectations and are subject to risks and uncertainties which may cause results to differ materially and adversely from the statements contained herein. Such statements include, but are not limited to, statements regarding Gain Therapeutics, Inc. (Gain) expected use of the proceeds from the Series B financing round; the market opportunity for Gain’s product candidates; and the business strategies and development plans of Gain. Some of the potential risks and uncertainties that could cause actual results to differ from those predicted include Gain’s ability to: make commercially available its products and technologies in a timely manner or at all; enter into other strategic alliances, including arrangements for the development and distribution of its products; obtain intellectual property protection for its assets; accurately estimate its expenses and cash burn and raise additional funds when necessary. Undue reliance should not be placed on forward-looking statements, which speak only as of the date they are made. Except as required by law, Gain does not undertake any obligation to update any forward-looking statements to reflect new information, events or circumstances after the date they are made, or to reflect the occurrence of unanticipated events.

Gain Therapeutics Investor Contact:

Daniel Ferry
LifeSci Advisors
+1 617-430-7576
[email protected]

Gain Therapeutics Media Contact:

Cait Williamson, Ph.D.
LifeSci Communications
+1 646-751-4366
[email protected]

CHANDLER, Ariz., Feb. 02, 2021 (GLOBE NEWSWIRE) — Applications such as data analytics, autonomous-driving and medical diagnostics are driving extraordinary demands for machine learning and hyperscale compute infrastructure. To meet these demands, Microchip Technology Inc. (Nasdaq: MCHP) today announced the world’s first PCI Express (PCIe) 5.0 switch solutions — the Switchtec PFX PCIe 5.0 family — doubling the interconnect performance for dense compute, high speed networking and NVM Express^® (NVMe^®) storage. Together with the XpressConnect^™ retimers, Microchip is the industry’s only supplier of both PCIe Gen 5 switches and PCIe Gen 5 retimer products, delivering a complete portfolio of PCIe Gen 5 infrastructure solutions with proven interoperability. 

“Accelerators, graphic processing units (GPUs), central processing units (CPUs) and high-speed network adapters continue to drive the need for higher performance PCIe infrastructure. Microchip’s introduction of the world’s first PCIe 5.0 switch doubles the PCIe Gen 4 interconnect link rates to 32 GT/s to support the most demanding next-generation machine learning platforms,” said Andrew Dieckmann, associate vice president of marketing and applications engineering for Microchip’s data center solutions business unit. “Coupled with our XpressConnect family of PCIe 5.0 and Compute Express Link^™ (CXL^™) 1.1/2.0 retimers, Microchip offers the industry’s broadest portfolio of PCIe Gen 5 infrastructure solutions with the lowest latency and end-to-end interoperability.”

The Switchtec PFX PCIe 5.0 switch family comprises high density, high reliability switches supporting 28 lanes to 100 lanes and up to 48 non-transparent bridges (NTBs). The Switchtec technology devices support high reliability capabilities, including hot-and surprise-plug as well as secure boot authentication. With PCIe 5.0 data rates of 32 GT/s, signal integrity and complex system topologies pose significant development and debug challenges. To accelerate time-to-market, the Switchtec PFX PCIe 5.0 switch provides a comprehensive suite of debug and diagnostic features including sophisticated internal PCIe analyzers supporting Transaction Layer Packet (TLP) generation and analysis and on-chip non-obtrusive SerDes eye capture capabilities. Rapid system bring-up and debug is further supported with ChipLink — an intuitive graphical user interface (GUI) based device configuration and topology viewer that provides full access to the PFX PCIe switch’s registers, counters, diagnostics and forensic capture capabilities.

“Intel’s upcoming Sapphire Rapids Xeon processors will implement PCI Express 5.0 and Compute Express Link running up to 32.0 GT/s to deliver the low-latency and high-bandwidth I/O solutions our customers need to deploy,” said Dr. Debendra Das Sharma, Intel fellow and director of I/O technology and standards. “We are pleased to see Microchip’s PCIe 5.0 switch and retimer investment strengthen the ecosystem and drive broader deployment of PCIe 5.0 and CXL enabled solutions.”

Development Tools

Microchip has released a full set of design-in collateral, reference designs, evaluation boards and tools to support customers building systems that take advantage of the high-bandwidth of PCIe 5.0.

In addition to PCIe technology, Microchip also provides data center infrastructure builders worldwide with total system solutions including RAID over NVMe, storage, memory, timing and synchronization systems, stand-alone secure boot, secure firmware and authentication, wireless products, touch-enabled displays to configure and monitor data center equipment and predictive fan controls.

Availability

The Switchtec PFX PCIe 5.0 family of switches are sampling now to qualified customers. For additional information, contact a Microchip sales representative.

Resources
High-res image available through Flickr or editorial contact (feel free to publish):

• Application image: https://www.flickr.com/photos/microchiptechnology/50808286076

About Microchip Technology

Microchip Technology Inc. is a leading provider of smart, connected and secure embedded control solutions. Its easy-to-use development tools and comprehensive product portfolio enable customers to create optimal designs which reduce risk while lowering total system cost and time to market. The company’s solutions serve more than 120,000 customers across the industrial, automotive, consumer, aerospace and defense, communications and computing markets. Headquartered in Chandler, Arizona, Microchip offers outstanding technical support along with dependable delivery and quality. For more information, visit the Microchip website at www.microchip.com.

Note: The Microchip name and logo and the Microchip logo are registered trademarks of Microchip Technology Incorporated in the U.S.A. and other countries. Switchtec and XpressConnect are trademarks of Microchip Technology Incorporated in the U.S.A. and other countries. All other trademarks mentioned herein are the property of their respective companies.

Intel, the Intel logo and other Intel marks are trademarks of Intel Corporation or its subsidiaries.  

Editorial Contact:	Reader Inquiries:
Chelsey Kruger	1-888-624-7435
480-792-5047
[email protected]

BOSTON, Feb. 02, 2021 (GLOBE NEWSWIRE) — X4 Pharmaceuticals, Inc. (Nasdaq: XFOR), a leader in the discovery and development of novel therapies targeting diseases resulting from dysfunction of the CXCR4 pathway, today announced that, on January 29, 2021, the Compensation Committee of X4’s Board of Directors issued an inducement award to new employees under the X4 Pharmaceuticals, Inc. 2019 Inducement Equity Incentive Plan (the “2019 Inducement Plan”). The 2019 Inducement Plan is used exclusively for the grant of equity awards to individuals who were not previously an employee of X4. The inducement awards consist of options to purchase an aggregate of 7,450 shares of X4’s common stock and were granted as an inducement material to the new employees entering into employment with X4 in accordance with Nasdaq Listing Rule 5635(c)(4).

The options have a ten-year term and an exercise price of $7.81 per share, which is equal to the closing price of X4’s common stock on January 29, 2021. Each option will vest over a four-year period, with 25% of the shares vesting after 12 months and the remaining shares vesting monthly over the following 36 months, subject to the employee’s continued employment with X4 on such vesting dates. The options are subject to the terms and conditions of the 2019 Inducement Plan and the terms and conditions of an award agreement covering the grant.

About X4 Pharmaceuticals, Inc.

X4 Pharmaceuticals is a late-stage clinical biopharmaceutical company and a leader in the discovery and development of novel therapies for the treatment of diseases resulting from dysfunction of the CXCR4 pathway, with a focus on rare diseases and those with limited treatment options. The company’s lead candidate, mavorixafor, is a first-in-class, small molecule antagonist of chemokine receptor CXCR4 being developed as a once-daily oral therapy. X4 believes that inhibition of the CXCR4 receptor creates the potential for mavorixafor to provide therapeutic benefit across a wide variety of diseases, including primary immunodeficiencies and certain types of cancer. The efficacy and safety of mavorixafor, dosed once daily, is currently being evaluated in a global Phase 3 clinical trial in patients with WHIM syndrome, and in two Phase 1b clinical trials – in combination with ibrutinib in patients with Waldenstrom macroglobulinemia, and as monotherapy in patients with severe congenital neutropenia (SCN). X4 is continuing to leverage its insights into CXCR4 biology at its corporate headquarters in Boston, Massachusetts and at its research facility in Vienna, Austria, and is developing additional product candidates. For more information, please visit www.x4pharma.com.

Investors and Media:

Daniel Ferry
Managing Director
LifeSci Advisors
[email protected] 
(617) 430-7576

Mónica Rouco Molina
Senior Account Executive
LifeSci Communications
[email protected]

Florida and Germany, Feb. 02, 2021 (GLOBE NEWSWIRE) — via NewMediaWire — Under the banner The BlueTech Alliance, Energy And Water Development Corp (OTCQB:EAWD) and ENVELON UG, a producer and engineering service provider for solar panels, have signed a comprehensive agreement for production of so-called Solar Powered Atmospheric Water Towers (eAWGT). 

The Solar Powered Atmosphere Water Generation Towers (eAWGT), a stand-alone but also building attached the Solar block, sizes 10 meters long wide, 8 meters high, and would be able to generate 10,000 Liters of water per day, completely independent of use of ground water or fossil fuels.  

According to the World Water Council, the tripling of the world’s population in the 20th century increased the use of renewable water resources six-fold. This growth and the increased industrialization and urbanization, has resulted as an increasing demand for water, even in developed and high income countries, which tend to use more water for energy generation and industry, for example the water supply for Tesla’s upcoming factory in Germany, which has been a topic of concern for some residents of nearby communities and for TESLA itself.   The eAWGT represents an immediate and sustainable solution for the water crisis in the manufacturing industry and we are pleased to find a partner in Germany that provides the know-how and technology for solar energy generation, Ralph Hofmeier – CEO of EAWD stated. This alliance helps us to further develop our products and to deliver the requested volume of water and energy generation products for the worldwide demand, Mr. Hofmeier concluded. 

ENVELON UG is a producer and engineering service provider for solar panels that are typically used for the building envelope of public buildings, office and/or big residential buildings. With the BlueTech Alliance, ENVELON UG starts to transfer its technology to a variety of applications, now including the Self-Sufficient Energy Powered Atmosphere Water Generation Systems (eAWGs), as well as this new development of building-attached eAWGT, Mr. Jochen Weick, Founder and CEO of ENVELON UG, stated. With the establishment of the BlueTech Alliance with EAWD, we extend our product range in the segment of infrastructure technology, engineering and services for projects; we are looking forward to seeing the first serial products to be built in Hamburg, Mr. Weick concluded. 

About Energy and Water Development (OTCQB:EAWD).

Energy and Water Development Corporation is a green-tech engineering solution company focused on delivering water and energy to extreme environments. The Company offers design, construction, maintenance, and specialty consulting services to private companies, government entities and non-government organizations (NGOs). EAWD builds water and energy systems out of already-existing, proven technologies, utilizing their technical know-how to customize solutions to their clients’ needs. The Company’s website is: www.eawctechnologies.com

About ENVELON UG.

ENVELON is German-based producer and engineering service provider for fully integrated solutions for the building envelope. According to the company´s mission, “Turn on the building envelope,” ENVELON´s product MATERIA is an active facade material that can replace classic building material without comprising on the esthetical quality. The main applications are public building, commercial and office buildings as well as big residential buildings. In cooperation with its wide-ranged network of companies ENVELON delivers full solutions including turn-key solutions for solar facades. For more details, visit www.envelon.de

Forward-Looking Statements

This press release may contain forward-looking statements. The words “believe,” “expect,” “should,” “intend,” “estimate,” “projects,” variations of such words and similar expressions identify forward-looking statements, but their absence does not mean that a statement is not a forward-looking statement. These forward-looking statements are based upon the Company’s current expectations and are subject to a number of risks, uncertainties and assumptions. The Company undertakes no obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise. Among the important factors that could cause actual results to differ significantly from those expressed or implied by such forward-looking statements are risks that are detailed in the Company’s filings.

Contact Information:

Energy and Water Development Corp.

Irma Velazquez, Chief Operating Officer

Email: [email protected]

Tel. +1 347 871 8927

Tel. +49 179 911 9256

Attachment

• EAWD